Inhibitor Therapeutics, Inc.
INTI evidence brief
What we can confirm
- BioSniper Score:
- 2.4 / 10
- Market Cap:
- $17.5M
- Lead Asset:
- suba-itraconazole (Preclinical)
What it means
What to watch
Prepared research question
What matters most for INTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INTI
Inhibitor Therapeutics, Inc. (INTI) is a pharmaceutical development company focused on developing and commercializing innovative therapeutics, currently advancing an itraconazole program for Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome) with a revised regulatory strategy and a novel formulation under development.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$17.5M
Cash Runway
—
Lead Asset
suba-itraconazole (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Inhibitor Therapeutics, Inc..
Inhibitor Therapeutics, Inc. (INTI) is a pharmaceutical development company focused on developing and commercializing innovative therapeutics, currently advancing an itraconazole program for Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome) with a revised regulatory strategy and a novel formulation under development.
- Cash & equivalents of $0.5M as of 2026-06-30 [sec]
- Net income of -$0.6M as of 2026-06-30 [sec]
- Shareholders' equity of -$2.6M as of 2026-06-30 [sec]
- Revised regulatory strategy for itraconazole in Basal Cell Carcinoma Nevus Syndrome (BCCNS) [news · 2026-09-08]
- Engaged Avior Bio, Inc. to develop a novel formulation of itraconazole; PK crossover study expected to take approximately six weeks [sec_mda · as of 2026-03-26]
What works
- The company has a revised regulatory strategy for itraconazole in BCCNS, indicating active progress in its lead program [news · 2026-09-08]
- Avior Bio has completed formulation development for a novel itraconazole formulation, and a PK crossover study is underway to support a new pre-IND and NDA [sec_mda · as of 2026-03-26]
What to weigh
- Cash & equivalents are very low at $0.5M as of 2026-06-30, which may constrain operations and development [sec]
- Shareholders' equity is negative at -$2.6M as of 2026-06-30, indicating accumulated losses exceed equity [sec]
- The company's net income was -$0.6M as of 2026-06-30, reflecting ongoing operating losses [sec]
From the filings
Quoted directly from source documents.
Revised regulatory strategy for itraconazole in BCCNS
“Recent progress includes a revised regulatory strategy for itraconazole in Basal Cell Carcinoma Nevus Syndrome”
News · September 8, 2026
PK crossover study expected to take approximately six weeks
“The PK crossover study is expected to take approximately six weeks to comple”
SEC MD&A · March 26, 2026
Risks & what to watch (3)›
Key risks
- Low cash runway — Cash & equivalents of only $0.5M as of 2026-06-30 may limit ability to fund operations and development [sec]
- Negative shareholders' equity — Shareholders' equity of -$2.6M as of 2026-06-30 indicates accumulated losses exceed equity [sec]
- Ongoing net losses — Net income of -$0.6M as of 2026-06-30 reflects continued operating losses [sec]
What to watch
- Completion of the PK crossover study for the novel itraconazole formulation, expected to take approximately six weeks from March 2026 [sec_mda · as of 2026-03-26]
- Outcome of the revised regulatory strategy for itraconazole in BCCNS [news · 2026-09-08]
- Annual stockholder meeting on September 15, 2026, where key developments may be discussed [news · 2026-09-08]
Sources: News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Inhibitor Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inhibitor Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$614K
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 0.4%
- Days to cover
- 0.1
- Shares short
- 19,880
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INTI short interestFrequently asked questions
What is the AI investment thesis for Inhibitor Therapeutics, Inc.?
Inhibitor Therapeutics, Inc. (INTI) is a pharmaceutical development company focused on developing and commercializing innovative therapeutics, currently advancing an itraconazole program for Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome) with a revised regulatory strategy and a novel formulation under development.
What is Inhibitor Therapeutics, Inc.'s lead drug candidate?
Inhibitor Therapeutics, Inc.'s most advanced tracked candidate is suba-itraconazole (Preclinical) for Lung cancer.
Who is the CEO of Inhibitor Therapeutics, Inc.?
Dr. Francis E. O'Donnell Jr., M.D. is the chief executive officer of Inhibitor Therapeutics, Inc. (INTI).
Where is Inhibitor Therapeutics, Inc. headquartered?
Inhibitor Therapeutics, Inc. (INTI) is headquartered in Tampa, FL, United States.
What therapeutic areas does Inhibitor Therapeutics, Inc. focus on?
Inhibitor Therapeutics, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.